Ben Creelan
Physician · H. Lee Moffitt Cancer Center and Research Institute
Credentials: · · · ·
History
- 2010–2012
Medical Oncology
Research
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2017 · 2,096 citations
Cancer Cell · 2018 · 880 citations
Nature Medicine · 2021 · Co-first of 26 authors · Corresponding · 374 citations
27 papers
22 papers
21 papers
20 papers
19 papers
11 papers
10 papers
8 papers · 1 as a resident
Clinical trials
- 2023–2027
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Principal investigator · Recruiting · Phase 1
H. Lee Moffitt Cancer Center and Research Institute
- 2017–2023
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 1
H. Lee Moffitt Cancer Center and Research Institute
- 2014–2021
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
Principal investigator · Completed · Phase 1
MedImmune LLC
- 2013–2019
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Principal investigator · Completed · Phase 1
H. Lee Moffitt Cancer Center and Research Institute